While CuS-SF@CMV nanoparticles kill hepatoma cells by CuS-mediated PTT, sorafenib and anti-VEGFR antibodies inhibit tumour angiogenesis through the PI3K/AKT and Ras/Raf/MEK/ERK pathways to achieve continuous inhibition against tumour metastasis (117). Here, MAP2K7 is linked to neoplasm.